



# The Leading Brand of Plasma Products in China








## Quality Management System

- GMP and ISO9001/ISO14001/OHSAS18001 Approved
- Quality management in the plasmapheresis centers, careful selection of healthy and qualified plasma donors
- Transportation of final products under strict cold-chain (2-8°C) conditions
- The test for Anti-HCV, Anti-HIV 1/2 and HBsAg and also NAT-Testing is done several times at different steps during the production process
- Unique technology of double virus inactivation without protective agents (patents granted in US, Australia, China)
- 90 Days Inventory Hold and Look-Back Procedures
- Inspected and licensed by CFDA and NIFDC

## Leading brand in China, excellent quality and customer tailored service


- Expert and leader in the Chinese plasma product manufacturing industry
- High purity, high titer, high biological activity and wide antibody profile
- Broad sales network, scientific based promotion, good after sales service


# SUYA PRODUCTS


Product	Dosage Forms	Shelf Life	Indications
 <b>SUYA-IV™</b> Human Immunoglobulin (pH4) for Intravenous Injection (IVIG) (5%) Liquid Solution Ready to Use	5g/vial (100ml) 2.5g/vial (50ml) 1.25g/vial (25ml)	The product is stable at 2-8°C for 3 years	<ul style="list-style-type: none"> <li>-Primary Immunodeficiency Diseases (PID)</li> <li>-Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment</li> <li>-Immunomodulatory therapy:               <ul style="list-style-type: none"> <li>•Idiopathic Thrombocytopenic Purpura (ITP), in adults or children with a high risk of bleeding or prior to surgery to correct platelet counts</li> <li>•Kawasaki disease</li> <li>•Guillain-Barré Syndrome (GBS)</li> </ul> </li> </ul>
 <b>SUYA-HBIV™</b> Human Hepatitis B Immunoglobulin (pH4) for Intravenous Injection Liquid Solution Ready to Use	2000IU/vial (20ml)	The product is stable at 2-8°C for 3 years	<ul style="list-style-type: none"> <li>-Prevention for hepatitis B virus-infection after liver transplantation for hepatitis B induced liver failure</li> </ul>
 <b>SUYA-HB™</b> Human Hepatitis B Immunoglobulin Liquid Solution Ready to Use	400IU/vial (4ml) 200IU/vial (2ml) 100IU/vial (2ml)	The product is stable at 2-8°C for 2 years	<ul style="list-style-type: none"> <li>-Post-exposure prophylaxis in persons who did not receive prior vaccinations, or whose prior vaccination regimen is incomplete, or when hepatitis B antibody levels are inadequate (&lt;10 IU/L)</li> <li>-Post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to HBsAg-positive or suspected HBsAg-positive material, for example, by needle, oral ingestion or sexual exposure</li> <li>-For prophylaxis in infants born to HBsAg-positive mothers</li> <li>-For prophylaxis of hepatitis B and suitable for use in liver transplantation</li> </ul>
 <b>SUYA-HT™</b> Human Tetanus Immunoglobulin Liquid Solution Ready to Use	500IU/vial (5ml) 250IU/vial (2.5ml)	The product is stable at 2-8°C for 2 years	<ul style="list-style-type: none"> <li>-Post-exposure prophylaxis:               <ul style="list-style-type: none"> <li>Immediate prophylaxis after tetanus prone injuries in patients not adequately vaccinated, in patients whose immunisation status is not known with certainty, and in patients with severe deficiency in antibody production</li> </ul> </li> <li>-Therapy of clinically manifest tetanus:               <ul style="list-style-type: none"> <li>Active tetanus vaccination should always be administered in conjunction with tetanus immunoglobulin unless there are contraindications or confirmation of adequate vaccination</li> </ul> </li> </ul>
 <b>SUYA-HR™</b> Human Rabies Immunoglobulin Liquid Solution Ready to Use	500IU/vial (5ml) 200IU/vial (2ml) 100IU/vial (1ml)	The product is stable at 2-8°C for 2 years	<ul style="list-style-type: none"> <li>- Post-exposure prophylaxis of rabies infection in persons after exposure to scratches, bites or other injuries including mucous membrane contamination with infectious tissue, such as saliva, caused by a suspected rabid animal</li> <li>- Human rabies immunoglobulin must always be used in combination with a rabies vaccine</li> </ul>
 <b>SUYA-IM™</b> Human Immunoglobulin For Intramuscular Injection (10%) Liquid Solution Ready to Use	300mg/vial (3ml) 150mg/vial (1.5ml)	The product is stable at 2-8°C for 3 years	<ul style="list-style-type: none"> <li>-Indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia</li> <li>-In combination with antibiotics can promote its curative effects on certain severe bacterial and viral infections</li> </ul>
 <b>SUYA-ALB™</b> Human Albumin (20%) Liquid Solution Ready to Use	20g/vial (100ml) 12.5g/vial (62.5ml) 10g/vial (50ml) 5g/vial (25ml) 2g/vial (10ml)	The product is stable at 2-8°C for 5 years  The product is stable at room temperature (below 30°C) for 3 years	<ul style="list-style-type: none"> <li>-Shock caused by blood loss, trauma and burn</li> <li>-Increased intracranial pressure caused by cerebral edema and injury</li> <li>-Edema or ascites caused by hepatic cirrhosis and nephrosis</li> <li>-Prevention and treatment of hypoproteinemia</li> <li>-Hyperbilirubinemia in new born babies</li> <li>-Supplementary treatment of cardiopulmonary shunt, fire burn and hemodialysis; treatment of adult respiratory distress syndrome</li> </ul>




**SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.**

 The 32<sup>nd</sup> Floor, First City Plaza, No. 308 of Shuncheng Street, Chengdu-610017, P.R.China

 Tel: +86 28 86623007, 86623179, 86621396

 Fax: +86 28 86623007

 E-mail: gmb@shuyang.com

 www.shuyang.com